The carbohydrate CT 1 is expressed in topographically fixed glomeruli in the mouse olfactory bulb

K. Lineburg,D. Amaya,J. Ekberg,Fatemeh Chehrehasa,Alan,Mackay-Sim,Paul T. Martin,B. Key,J. A. John

Abstract:

What problem does this paper attempt to address?

Clinical Efficacy and Safety of Different Doses of Sildenafil in the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Network Meta-analysis

Linli Sun,Chunxia Wang,Yulu Zhou,Wei Sun,Chunjiang Wang

DOI: https://doi.org/10.3389/fphar.2021.697287

IF: 5.6

2021-09-24

Frontiers in Pharmacology

Abstract:Objective: To evaluate the efficacy and safety of different doses of sildenafil for persistent pulmonary hypertension of the newborn (PPHN) with Bayesian random effects network meta-analysis. Methods: We searched Chinese and English databases for randomized controlled trials (RCTs) concerning sildenafil in newborns with persistent pulmonary hypertension from 1998 to December 2020. Results: Twenty-two RCTs including over 2131 patients were included. Sildenafil was administered by nasal feeding at 0.3–2 mg/kg every 4–6 h. The network meta-analysis revealed that 1.5 mg/kg of sildenafil led to a significant decrease in pulmonary artery systolic pressure (PASP) compared with 0.3 and 0.6 mg/kg ( p < 0.05); 1.5 mg/kg was better than 0.3, 0.5, and 1.0 mg/kg at increasing the partial pressure of oxygen (PaO 2 ) ( p < 0.05); 1.5 mg/kg was better than 0.5, 0.6 and 1.0 mg/kg at reducing the partial pressure of carbon dioxide (PaCO 2 ) ( p < 0.05); and 1.2 mg/kg was better than 0.3, 0.5 and 1.0 mg/kg at increasing the arterial oxygen saturation (SaO 2 ) ( p < 0.05). The surface under the cumulative ranking analysis (SUCRA) results showed that 1.5 mg/kg had the best effect in reducing PASP (SUCRA = 92.0%, moderate certainty evidence) and PaCO 2 (91.1%) and increasing PaO 2 (SUCRA = 79.3%, moderate certainty evidence), 2.0 mg/kg had the best effect in increasing SaO 2 (SUCRA = 88.6%, moderate certainty evidence) and total effective rate (SUCRA = 93.5%, low certainty of evidence)). No severe adverse effects were observed with the different doses of sildenafil. Conclusion: Different doses of sildenafil can significantly improve PPHN, and 1.5 mg/kg of sildenafil has better clinical efficacy and does not increase the probability of adverse reactions.

pharmacology & pharmacy
Efficacy of sildenafil in persistent pulmonary hypertension of the newborn.

Muhammad Naveed,Fazal ur Rehman,Khurram Shahnawaz,Farhan Zahoor,Bushra Madni,Muhammad Imran

DOI: https://doi.org/10.29309/tpmj/2022.29.04.6617

2022-03-31

The Professional Medical Journal

Abstract:Objective: To find out efficacy of sildenafil for the treatment of persistent pulmonary hypertension of the newborn (PPHN). Study Design: Observational study. Setting: Department of Neonatology, Sughra Shafi Medical Complex, Sahara Medical College, Narowal. Period: May 2020 to April 2021. Material & Methods: A total of 22 neonates of both genders with diagnosis of PPHN were enrolled during the study period. Demographic characteristic along with information about perinatal and postnatal characteristics were recorded among all neonates at the time of admission. X-ray chest were asked. Oral sildenafil was administered as 2mg/kg per dose thrice a day to all study cases and continued till extubation. Outcome was recorded on the basis of difference in FiO2 need after initiating sildenafil, time required to get ventilator off or mortality. Results: Out of a total of 22 neonates, 13 (59.1%) were male. Majority of the neonates, 15 (68.2%) were term newborns. Mode of delivery was lower segment cesarean section in 17 (77.3%) cases. APGAR score at 5 minutes was between 7 to 10 in 13 (59.1%) newborns. There were 13 (59.1%) newborns who required immediate resuscitation following birth. Meconium aspiration syndrome was the commonest associated condition found among 8 (36.4%) neonates. As per echocardiographic findings, 13 (59.1%) neonates had severe PPHN, 5 (22.7%) moderate and 4 (18.2%) mild. Mean oxygenation index at the time of admission was noted to be 46+14. Inotropic support was administered to 19 (86.4%) cases. Mean length of neonatal intensive care unit was 15+5 days. Mortality was reported among 10 (45.4%) neonates. Conclusion: Oral sildenafil was found to be a promising option for the treatment of neonates having PPHN. Oral sildenafil was found to successfully improve oxygenation among neonates having PPHN.
Effectiveness of oral sildenafil for neonates with persistent pulmonary hypertension of newborn (PPHN): a prospective study in a tertiary care hospital

Amber Kamran,Nida Rafiq,Adeel Khalid,Fatima Amin,Veena Kumari,Abdul Sattar Shaikh,Sameer Saleem Tebha,Najma Patel

DOI: https://doi.org/10.1080/14767058.2021.1923003

2021-05-12

Abstract:The prevalence of persistent pulmonary hypertension of newborn (PPHN) has been estimated 1.9/1000 live births. Although the efficacy of inhaled nitric oxide and extracorporeal membrane oxygenation in PPHN is well established but it is difficult to administer and monitor in resource limited countries. Owing to this, other treatment options need to be evaluated.This is a prospective observational study conducted in the Pediatric Cardiology Department, NICVD, Karachi, from February 2020 to October 2020 after the approval from the Institutional Ethical Review Committee. All the neonates referred to our Unit were screened by echocardiography (echo) and those who fulfilled the inclusion criteria were included. Echo were done before starting sildenafil and after 72 h to assess the pressure gradient across tricuspid valve and right to left or bidirectional shunt across patent ductus arteriosus , patent foramen ovale , or both. Sildenafil was started with a dose of 1 mg/kg/dose thrice a day and increased to 2 mg/kg/dose after 48 h if partial pressure of oxygen (PO<a href="#">1</a> Thérèse P. Persistent pulmonary hypertension of the newborn. Paediatr Respir Rev. 2006;7:175–176.<a href="/servlet/linkout?suffix=CIT0001&dbid=16&doi=10.1080%2F14767058.2021.1923003&key=10.1016%2Fj.prrv.2006.04.211">[Crossref]</a>, <a href="/servlet/linkout?suffix=CIT0001&dbid=8&doi=10.1080%2F14767058.2021.1923003&key=16938639">[PubMed]</a> , <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=175-176&author=P.+Th%C3%A9r%C3%A8se&title=Persistent+pulmonary+hypertension+of+the+newborn">[Google Scholar]</a>] did not increase. In neonates who did not respond to increased dose of Sildenafil were added on oral Bosentan 1 mg/kg/dose twice a day.Total 82 newborns were enrolled. Fifty-two patients improved after 48 h so were continued on same treatment. Sildenafil dose was increased in 30 (37.9%) patients whose PO2 did not increase to at least 10% from baseline after 48 h of starting treatment. Three patients expired within 48–72 h. Out of 27 remaining patients, only four responded whereas 23 patients did not show any improvement. In these patients, Bosentan was supplemented along with sildenafil.The results of our study show effectiveness of oral Sildenafil in treating PPHN. The overall improvement observed in the patients was overwhelming. Combination of Sildenafil with Bosentan is beneficial in patients who did not respond on Sildenafil alone.
Use of sildenafil for the treatment of neonatal persistent pulmonary hypertension

José de Ribamar Barroso Jucá Neto,Ângela Rocha Mapurunga,Angelica Gomes Belchior,Felipe Rabelo Costa,Vitor Teixeira Boscov

DOI: https://doi.org/10.33448/rsd-v13i1.44910

2024-01-31

Abstract:Introduction: Persistent pulmonary hypertension of the newborn is a neonatal respiratory and vascular pathology with a high mortality rate. Furthermore, its prevalence is 1 to 2 per 1000 live births, accounting for 8%-10% of neonatal deaths. The therapeutic approach involves supporting pulmonary recruitment and pharmacological vasodilation, most notably sildenafil. Methodology: The study is a narrative review of the literature that was carried out from the PUBMED database using the keywords “Persistent Pulmonary Hypertension of the Newborn” and “Sildenafil”, with the time filter in the last 30 years (1994- 2023). Discussion: Physiologically, during fetal life, the lungs remain filled with fluids, but immediately after birth, pulmonary vascular resistance decreases drastically, allowing alveolar oxygen tension and ventilation to be possible. However, in the pathogenesis of neonatal persistent pulmonary hypertension, there is an increase in pulmonary vascular resistance and remodeling of the vascular structure after birth, which potentiate this exaggerated vasoconstriction. Therefore, the standard exam for investigating the pathology is echocardiography. Sildenafil is a drug used to treat neonatal persistent pulmonary hypertension, as it enhances better blood flow and better delivery of oxygen to tissues, through its physiopharmacology aimed at vasodilation secondary to inhibition of phosphodiesterase-5. Conclusion: Neonatal persistent pulmonary hypertension is still one of the main neonatal pathologies with high morbidity and mortality in the neonatal population, due to the complexity of presentations and the variation in therapeutic responses to pharmacotherapy.
The outcome of oral sildenafil therapy on persistent pulmonary hypertension of the newborn with respiratory distress

Esaad M. Monazea,Sahar S. Khattab,Asmaa A.W. Ebrahim,Layla A. Mohamed,Howayda A.A.R. Ahmed

DOI: https://doi.org/10.4103/sjamf.sjamf_72_20

2020-01-01

The Scientific Journal of Al-Azhar Medical Faculty, Girls

Abstract:Background Persistent pulmonary hypertension (PPHN) is defined as failure of normal pulmonary vascular adaptation at or soon after birth, resulting in a persistent high pulmonary vascular resistance, which leads to diminished pulmonary blood flow and shunting of unoxygenated blood into systemic circulation through an opened foramen ovale and/or the ductus arteriosus. The prevalence of this syndrome is about 1.9/1000 in the population of neonates born at term. Objective The aim was to evaluate the efficacy and safety of oral sildenafil in the treatment of PPHN. Patients and methods This prospective interventional study was conducted on 50 neonates who were of more than or equal to 37 weeks gestational age and less than 3 days old and were diagnosed as PPHN by echocardiogram and had an oxygenation index (OI) more than or equal to 20. All included cases were given oral sildenafil as per the study protocol with a starting dose of 0.5–2 mg/kg/dose. OI, oxygen saturation, alveolar arterial oxygen gradient, and mean airway pressure were monitored serially. Results This study showed a significant decrease in OI after 30 min of starting treatment and after 24 h of treatment in the studied cases 16.1±1.7 ( P =0.010); also, there was a significant decrease in ESPAP ? after treatment estimated by ECHO from mean 49.4±5,9 to 42.5±5.7 ( P <0.001). Furthermore, this study showed a significant decrease in brain-type natriuretic peptide in studied cases after treatment with sildenafil. Conclusion Oral sildenafil may be of benefit in improving oxygenation in infants with PPHN as it can effectively improve OI and reduce right ventricular systolic pressure.
Effect of Sildenafil in Neonates with Persistent Pulmonary Hypertension: An Interventional Study

Jigar Jain,Jolly Vaishnav,Arif Vohra,Mansi Shah,Anika Goyal

DOI: https://doi.org/10.7860/ijnmr/2024/67870.2415

2024-01-01

Indian Journal of Neonatal Medicine and Research

Abstract:Introduction: Persistent Pulmonary Hypertension of the Newborn (PPHN) reflects a disruption of the normal perinatal circulatory transition and is characterised by high pulmonary artery pressure. Inhaled Nitric Oxide (iNO) is considered the mainstay of treatment for PPHN. However, many developing and resource limited countries do not have access to such expensive therapy. Therefore, sildenafil, due to its easy availability and low cost, becomes the most commonly used drug in the management of PPHN in such settings. Aim: To study the treatment response and outcomes of neonates who received sildenafil for the management of PPHN. Materials and Methods: The present hospital-based prospective interventional study was conducted in the Neonatal Intensive Care Unit (NICU), BJ Medical College, Civil Hospital, Ahmedabad, Gujarat, between May 1, 2020, and April 30, 2021. Study was conducted on neonates with meconium aspiration syndrome and/or severe birth asphyxia admitted to the NICU. A total of 48 neonates with Two Dimensional (2D) echocardiography-proven PPHN were enrolled. Baseline clinical parameters including heart rate, respiratory rate, preductal and postductal Saturation of Peripheral Oxygen (SpO2), Oxygenation Index (OI), Saturation Oxygen Distending Pressure Index (SOPI), and Non Invasive Blood Pressure (NIBP) were monitored every six hours. Neonates who were on invasive/ non invasive ventilation had their Fraction of Inspired Oxygen (FiO2), Positive End Expiratory Pressure (PEEP), Peak Inspiratory Pressure (PIP), respiratory rate and flow rate monitored every six hours. Data were statistically analysed using Analysis of Variance (ANOVA) test. Results: During the study period, a total of 1080 neonates were admitted with meconium aspiration syndrome and/or severe birth asphyxia, out of which 48 neonates showed findings suggestive of PPHN on 2D echocardiography. A statistically significant improvement in oxygenation after sildenafil treatment was indicated by a significant reduction in OI from 35.3±8.6 to 13.2±2.1 (p-value<0.001), a reduction in SOPI from 3.6±0.3 to 1.5±0.2 (p-value<0.001), a reduction in FiO2 (%) from 94.6±8.19 to 24.2±4.5 (p-value<0.001), an increase in Partial pressure of oxygen (PaO2) (mmHg) from 52±5.6 to 72±3.4 (p-value<0.001), and an increase in SpO2 (%) from 83.5±8.6 to 93.5±5.1 (p-value<0.001). Conclusion: The findings of the present study suggest that oral sildenafil can be successfully used to improve oxygenation in patients with PPHN, especially in a resource limited setting where facilities like Extracorporeal Membrane Oxygenation (ECMO) and iNO are not available, as demonstrated in the present study.
Comparison of the Effectiveness of Bosentan and Sildenafil in the Management of Persistent Pulmonary Arterial Hypertension in Neonates

Hanan Elsayed Kamel Bakry

DOI: https://doi.org/10.21608/ejhm.2022.268092

2022-10-01

The Egyptian Journal of Hospital Medicine

Abstract:Background: In newborns, persistent pulmonary hypertension (PPHN) poses a serious hazard to life. The principal treatment, inhaled nitric oxide, is believed to be unavailable in developing nations, where mortality is predicted to be between 10% and 20% higher. Objectives: This study aimed to assess the effectiveness, safety, and potential adverse reactions of bosentan and sildenafil when used in newborns with PPHN. Patients and Methods: Between July 2021 and August 2022, a double-blind clinical experiment was carried out at Damietta General Hospital's Neonatal Intensive Care Unit. In newborns with PPHN, the effectiveness, safety, and potential adverse reactions of bosentan and sildenafil were assessed. Comparisons were done between the two groups' echocardiographic results, length of oxygen reliance, need for invasive ventilator assistance, duration of medication, and short-term results such as: blood pressure, white blood cell, and haemoglobin counts. Results: Bosentan has comparable PAP-lowering and cardiac output-improving effects to sildenafil. Bosentan had a considerably shorter treatment period than sildenafil (P = 0.003). During 15 and 17 days, the oxygen need time was comparable between the two groups (P = 0.175). Both groups required invasive breathing support, which was equivalent (P = 0.867). The third echocardiographic research results, including pulmonic inadequacies (P = 0.183), tricuspid regurgitations (P = 0.357), and ejection fractions (P = 0.159), were comparable in the bosentan and sildenafil groups, despite pulmonary artery pressure (PAP) and the intensity of tricuspid valve inadequacy being higher before therapies. Conclusion: Neonatal PPHN is successfully treated with bosentan, which decreased it more quickly. Comparing to sildenafil, it is more effective at lowering PAP and lessens the degree of tricuspid valve dysfunction in a shorter period of time.
Oral Sildenafil in Infants With Persistent Pulmonary Hypertension of the Newborn: A Pilot Randomized Blinded Study

Hernando Baquero,Amed Soliz,Freddy Neira,Maria E. Venegas,Augusto Sola

DOI: https://doi.org/10.1542/peds.2005-0523

2006-04-01

PEDIATRICS

Abstract:BACKGROUND. Persistent pulmonary hypertension (PPHN) occurs in as many as 6.8 of 1000 live births. Mortality is ∼10% to 20% with high-frequency ventilation, surfactant, inhaled nitric oxide, and extracorporeal membrane oxygenation but is much higher when these therapies are not available. Sildenafil is a phosphodiesterase inhibitor type 5 that selectively reduces pulmonary vascular resistance. OBJECTIVE. Our goal was to evaluate the feasibility of using oral sildenafil and its effect on oxygenation in PPHN. DESIGN. This study was a proof-of-concept, randomized, masked study in infants >35.5 weeks' gestation and <3 days old with severe PPHN and oxygenation index (OI) >25 admitted to the NICU (Hospital Niño Jesús, Barranquilla, Colombia). The sildenafil solution was prepared from a 50-mg tablet. The first dose (1 mg/kg) or placebo was given by orogastric tube <30 minutes after randomization and every 6 hours. Preductal saturation and blood pressure were monitored continuously. OI was calculated every 6 hours. The main outcome variable was the effect of oral sildenafil on oxygenation. Sildenafil or placebo was discontinued when OI was <20 or if there was no significant change in OI after 36 hours. RESULTS. Six infants with an OI of >25 received placebo, and 7 received oral sildenafil at a median age of 25 hours. All infants were severely ill, on fraction of inspired oxygen 1.0, and with similar ventilatory parameters. Intragastric sildenafil and placebo were well tolerated. In the treatment group, OI improved in all infants within 6 to 30 hours, all showed a steady improvement in pulse oxygen saturation over time, and none had noticeable effect on blood pressure; 6 of 7 survived. In the placebo group, 1 of 6 infants survived. CONCLUSIONS. Oral sildenafil was administered easily and tolerated as well as placebo and improved OI in infants with severe PPHN, which suggests that oral sildenafil may be effective in the treatment of PPHN and underscores the need for a large, controlled trial.

pediatrics
Efficacy and Safety of IV Sildenafil in the Treatment of Newborn Infants with, or at Risk of, Persistent Pulmonary Hypertension of the Newborn (PPHN): A Multicenter, Randomized, Placebo-Controlled Trial

Christine M Pierce,Min H Zhang,Baldvin Jonsson,Dinu Iorga,Narayan Cheruvu,Cecile C Balagtas,Robin H Steinhorn

DOI: https://doi.org/10.1016/j.jpeds.2021.05.051

Abstract:Objective: To investigate the efficacy and safety of sildenafil added to inhaled nitric oxide (iNO) for newborn infants with persistent pulmonary hypertension of newborn (PPHN) or hypoxic respiratory failure (HRF) at risk of PPHN. Study design: Part A of a multinational, randomized, double-blind, placebo-controlled trial. Infants ≤96 hours' old, >34 weeks of gestation, receiving iNO (10-20 ppm on ≥50% FiO2) for PPHN or HRF at risk of PPHN, and oxygen index >15 to <60, were randomized (1:1) to intravenous (IV) sildenafil (loading: 0.1 mg/kg, over 30 minutes; maintenance: 0.03 mg/kg/h) or placebo, for up to 14 days. Coprimary end points were treatment failure rate (day 14/discharge) and time on iNO without treatment failure. Secondary end points included time on ventilation and oxygenation measures. Results: Of 87 infants screened, 29 were randomized to IV sildenafil and 30 to placebo; 13 discontinued treatment (sildenafil, n = 6; placebo: n = 7), including 3 deaths (sildenafil: n = 2; placebo: n = 1). Treatment failure rates did not differ with sildenafil (27.6%) vs placebo (20.0%; P = .4935). Mean time on iNO was not different with sildenafil (4.1 days) vs placebo (4.1 days; P = .9850). No differences were noted in secondary end points. Most common adverse events (AEs) with sildenafil (≥10% infants) were hypotension (n = 8/29), hypokalemia (n = 7/29), anemia, drug withdrawal syndrome (n = 4/29, each), and bradycardia (n = 3/29). One serious AE (hypotension) was considered treatment-related. Conclusions: IV sildenafil added to iNO was not superior to placebo in infants with PPHN or HRF at risk of PPHN. A review of AEs did not identify any pattern of events indicative of a safety concern with IV sildenafil. Infants will have developmental follow-up (Part B). TRIAL REGISTRATION CLINICALTRIALS.GOV: NCT01720524.
Study on sildenafil combined with inhalational nitric oxide therapy on the curative effects and serum levels of HIF-1α, ET-1, and calcium in neonatal pulmonary hypertension

G Liu,H-W Wu,Z-G Li

DOI: https://doi.org/10.26355/eurrev_201807_15529

Abstract:Objective: To explore the effect of sildenafil combined with inhalational nitric oxide (NO) therapy on the curative effects and serum levels of hypoxia-inducible factor (HIF)-1α, endothelin-1 (ET-1), and calcium in persistent pulmonary hypertension of the newborn (PPHN). Patients and methods: Eighty-six patients with neonatal pulmonary hypertension treated in Xuzhou Children's Hospital from March 2015 to February 2016 were randomly divided into the observation group and control group, treated with sildenafil and sildenafil combined with inhalational NO, respectively. The clinical efficacy of newborns in the two groups was compared. Fraction of inspiration O2 (FiO2), Oxygen Index (OI), blood oxygen partial pressure (PaO2), blood oxygen saturation (SpO2), and pulmonary arterial pressure of newborns in the two groups were compared before treatment and 2 h, 12 h, and 24 h after treatment. The serum levels of HIF-1α, ET-1, and calcium of patients in the two groups were compared before treatment and 3, 5, 7 days after treatment. Results: The total effective rate of the observation group (95.34%) was significantly higher than that of the control group (74.41%) (p<0.05). After treatment, FiO2, OI, and pulmonary arterial pressure of patients in the two groups decreased, and the decrease in the observation group was significantly lower than in the control group (p<0.05). After treatment, PaO2 and SpO2 of patients in the observation group were higher than those of the control group. The levels of HIF-1α and ET-1 of patients in the two groups decreased and were significantly lower in the observation group compared with the control group. The levels of calcium of patients in the two groups increased and were significantly higher in the observation group than the control group (p<0.05). Conclusions: Sildenafil combined with inhalational NO therapy for neonatal pulmonary hypertension can quickly improve oxygenation, effectively reduce pulmonary arterial hypertension, and is worthy of clinical application.
Genomic DNA extraction fromVictoria amazonica

D. Puchooa,S. S. S. Khoyratty

DOI: https://doi.org/10.1007/BF02772727

2004-06-01

Plant Molecular Biology Reporter

Abstract:
Perforation of the right ventricular free wall by an ICD lead in a patient with isolated noncompaction of the ventricular myocardium.

Yoshitaka Sakai,Yuichi Sato,S. Matsuo,S. Imai,T. Kunimasa,N. Matsumoto,S. Saito

DOI: https://doi.org/10.1016/J.IJCARD.2006.11.223

IF: 4.039

2007-05-02

International Journal of Cardiology

Abstract:
The use of Sildenafil in the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Review of the Literature

Nicoletta Iacovidou,Aggeliki Syggelou,Vassilios Fanos,Theodoros Xanthos

DOI: https://doi.org/10.2174/1381612811209023034

IF: 3.31

2012-05-01

Current Pharmaceutical Design

Abstract:Persistent pulmonary hypertension of the newborn (PPHN) is a serious and potentially fatal condition, characterized by hypoxemia due to increased pulmonary vascular resistance (PVR) with resultant shunting of pulmonary blood to the systemic circulation. Inhaled nitric oxide (iNO) has been considered a revolutionary treatment of PPHN. Data show that the use of iNO has reduced the need of ECMO in neonates with severe PPHN, while in moderate PPHN, iNO administration has been associated with a significant decrease in ventilatory support and prevented progression to severe PPHN. Not all neonates respond to iNO therapy though, and phosphodiesterase (PDE) inhibitors with their potent vasodilator properties have evolved as an alternative therapy or as an adjunct to the treatment of PPHN with iNO. There are ten families of PDE isoenzymes. PDE 5 is particularly prevalent in vascular smooth muscle (VSM) and PDE 5 inhibitors, such as sildenafil, have been used in clinical practice. This review provides a comprehensive account of existing data in the literature, from animal and clinical studies, on the use of sildenafil for the treatment of PPHN. Sildenafil may also have a role as a single mode of therapy, since in resource-limited settings the cost of iNO is a serious concern.

pharmacology & pharmacy
Comparison of treprostinil and oral sildenafil for the treatment of persistent pulmonary hypertension of the newborn: a retrospective cohort study

Enhuan Wei,Xiu-hua Chen,Si-Jia Zhou

DOI: https://doi.org/10.3389/fped.2023.1270712

IF: 3.569

2023-11-04

Frontiers in Pediatrics

Abstract:Background: This study aims to evaluate the effectiveness of treprostinil and oral sildenafil in managing persistent pulmonary hypertension of newborns (PPHN). Methods: We conducted a retrospective cohort study of 42 neonates with PPHN treated with continuous intravenous treprostinil or oral sildenafil from January 2020 to October 2022 in China. Outcomes assessed included echocardiographic pulmonary artery systolic pressure (PASP), shunt direction, and arterial blood gas measures. Results: Treprostinil lowered PASP and improved oxygenation significantly better than sildenafil on days 1, 2, and 3 of treatment ( P < 0.05). Treprostinil also corrected shunt direction faster than sildenafil ( P < 0.05). The duration of mechanical ventilation, length of NICU stay, and overall hospital stay did not significantly differ between the two groups ( P > 0.05). Conclusions: Treprostinil effectively lowers pulmonary artery pressure and improves oxygenation in neonates with PPHN, without being associated with severe complications. It may serve as a beneficial adjunct therapy for neonates with PPHN.

pediatrics
Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction : In-hospital and 30-day results of the PAMI stent pilot trial

G. Stone,B. Brodie,J. J. Griffin,M. Morice,C. Costantini,F. Goar,P. Overlie,J. Popma,J. McDonnell,Denise E. Jones,W. O’Neill,C. Grines

DOI: https://doi.org/10.1016/S0735-1097(97)00439-7

Abstract:
The Progress in the Treatment of Persistent Pulmonary Hypertension in Neonatal

Fang Sai,Du Lizhong

DOI: https://doi.org/10.3877/cma.j.issn.2096-1537.2019.03.012

2019-01-01

Abstract:Persistent pulmonary hypertension of neonatal (PPHN) refers to the continuous increase of pulmonary vascular resistance after birth, which causes the abnormal development from fetal circulation to ″adult″ type circulatory and the subsequent right to left shunt through atrial septum or arterial duct. Clinical symptoms include severe hypoxemia and even respiratory failure. PPHN can be seen in the congenital dysplasia of the lung, as well as in the substantial lung diseases. The incidence of the disease is around 0.2%, and mortality about 10%. In addition to the treatment of the underlying disease, timely and effective treatments like respiratory support and vasoactive drugs can significantly reduce the incidence and mortality of the disease. This article summarizes the current treatment progress in persistent pulmonary hypertension of neonatal, and provides useful information for clinicians. Key words: Neonates; Persistent pulmonary hypertension of neonatal; Treatment progress
Comparison of tadalafil and sildenafil in controlling neonatal persistent pulmonary hypertension

MarwaA Abdel Monem,HamedM El Sharkawy,AhmedA Abo ELezz,AshrafM Ibrahim

DOI: https://doi.org/10.4103/tmj.tmj_30_22

2023-09-15

Tanta Medical Journal

Abstract:Background Persistent pulmonary hypertension of the newborn (PPHN) is a multifactorial syndrome, with 0.43–6.8/1000 live birth incidence and 10–20% mortality rate. Aim To compare the efficacy of tadalafil and sildenafil in controlling PPHN. Patients and methods This prospective study was carried out on 40 neonates with PPHN. Patients were equally divided into two groups: group 1 received tadalafil (Cialis 10 mg), 1 mg/kg as a single dose for 48 h, and group 2 received sildenafil (Silden 25 mg), 1 mg/kg/8 h for 48 h. Echocardiography was done at the time of enrollment and 48 h after starting treatment measuring the change in estimated systolic pulmonary artery pressure (ESPAP), patent ductus arteriosus assessment, assessment of left ventricle functions, changes in oxygen saturation, and oxygen requirements. Results Both drugs were successful in improving oxygen saturation, decreasing oxygen requirements, and decreasing ESPAP. There was a significant difference before and after treatment in both groups, whereas the difference between the two groups was statistically insignificant ( P >0.05). Conclusion Tadalafil and sildenafil can similarly reduce ESPAP in neonates with PPHN. No serious short-term adverse effects of tadalafil and sildenafil were observed.
Comparison of Efficacy between Sildenafil Alone and Sildenafil with Milrinone for Treatment of Persistent Pulmonary Hypertension of the Newborn

Maksudur Rahman,Nondini Rahman Nupur,Mohammad Abdulla Al Mamun,Md. Monir Hossain

DOI: https://doi.org/10.36347/sjams.2021.v09i10.008

2021-10-11

Scholars Journal of Applied Medical Sciences

Abstract:Introduction: In persistent pulmonary hypertension of the newborn (PPHN), some neonates do not response to single pulmonary vasodilator drug, so recently combination therapy is being tried to decrease pulmonary artery systolic pressure (PASP). The aim of the study was to compare the efficacy of oral sildenafil alone with combination of oral sildenafil and milrinone in neonates suffering from PPHN. Methods: This RCT study was conducted in Dhaka Shishu (Children) Hospital, from July 2018 to June 2020. Sixty eight (68) term and near term neonates aged <10 days (34 cases in each group) with moderate to severe PPHN were taken. Monotherapy with oral sildenafil was given in group-A and combined therapy with oral sildenafil and i/v milrinone in Group-B. Serial echocardiography was done at before starting the therapy, at 3 days and at 5 days of treatment. Data regarding baseline characteristics, clinical features, PASP, PO2, Spo2, hospital stay, mortality and others investigations were recorded and analyzed with SPSS version-26. Results: Post treatment PASP was significantly reduced in group A (sildenafil) and group-B (sildenafil plus milrinone) (p<0.05). But in combination group PASP was more reduced than monotherapy group (p<0.05). Within the group, the oxygen saturation and PO2 significantly improved in both groups (p 0.05). Adrenaline infusion, hypotension and less hospital stay were significantly seen (P<0.05) in combination group. Conclusion: Combined therapy with oral sildenafil and milrinone are more effective than monotherapy with oral sildenafil in reduction of PASP. Both therapies are effective in improvement of oxygenation.
Safety and effect of sildenafil on treating paediatric pulmonary arterial hypertension: a meta-analysis on the randomised controlled trials

Qingyou Zhang,Bowen Xu,Jichen Lv,Zhijian Wang,Junbao Du

DOI: https://doi.org/10.1017/S104795112000311X

2020-01-01

Cardiology in the Young

Abstract:Background: Efficacy of sildenafil in treating paediatric pulmonary arterial hypertension is controversial. This systematic review aimed to explore the safety and effect of sildenafil on treating paediatric pulmonary arterial hypertension (PAH) through meta-analysis. Methods and results: In this study, the electronic databases, including the Cochran Library database, EMBASE, and MEDLINE were systemically retrieved to identify the related randomised controlled trials (RCTs). Two reviewers had independently completed study selection, data collection, and assessment of the bias risk. Amongst 938 articles researched according to our retrieval strategy, 15 papers that involved 673 cases had been screened. Relative to control group, the sildenafil group had markedly reduced mortality (RR = 0.25, 95% CI: 0.12-0.51; p < 0.0001), but difference within the mortality was not statistically significant between high- and low-dose sildenafil groups (p = 0.152). Nonetheless, difference of the mean pulmonary arterial pressure between sildenafil as well as control group was of no statistical significance. Differences in the length of hospital stay and the incidences of pulmonary hypertensive crisis between children with PAH and controls were of no statistical significance. However, the summary estimate favoured that sildenafil reduced the duration of mechanical ventilation time, as well as the length of ICU stay and inotropic support. Conclusions: Sildenafil therapy reduces the mortality of PAH patients, but its effects on the haemodynamic outcomes and other clinical outcomes are still unclear.
Effect of Sildenafil on Mortality in Term Neonates with Hypoxemic Respiratory Failure due to Persistent Pulmonary Hypertension (SIPHON) - A Randomised Control Trial

Deepti Thandaveshwara,Sushma Krishnegowda,Divya Hosur,Srinivasa Murthy Doreswamy

DOI: https://doi.org/10.3126/jnps.v41i2.32403

2021-11-03

Journal of Nepal Paediatric Society

Abstract:Introduction: Persistent Pulmonary Hypertension (PPHN) complicates the transition from intrauterine to extrauterine life in some neonates. Sildenafil is known to reduce pulmonary pressures. However, its effect on reducing mortality is unclear. This study is conducted to determine the effect of Sildenafil in reducing all-cause mortality rate in term newborns with hypoxemic respiratory failure due to pulmonary hypertension. Methods: This was a double-blinded randomised control trial done in a level 3 neonatal intensive care unit. Term neonates on mechanical ventilation with an Oxygenation Index (OI) > 15, and echocardiography suggesting PPHN were included in the study. The drug group received intravenous Sildenafil and the placebo group normal saline. The difference in the mortality rate between the two groups was analysed. Results: Eleven babies were randomised to the drug group and 12 to the placebo group. Both the groups matched in terms of their baseline characteristics. The difference in the drop of OI and right ventricular systolic pressure (RVSP) between the drug and placebo groups was not statistically significant. The relative risk of mortality was 0.436 in the intervention group (95% CI 0.105 to 1.80). The difference in the mortality rate was not statistically significant with P- value of 0.252. The rate of complications such as necrotising enterocolitis, sepsis, and pneumothorax was not different between the two groups. Conclusions: Intravenous sildenafil does not have any significant benefit over placebo in reducing all-cause mortality, oxygenation index, RVSP or complications when compared to placebo.

The carbohydrate CT 1 is expressed in topographically fixed glomeruli in the mouse olfactory bulb

Clinical Efficacy and Safety of Different Doses of Sildenafil in the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Network Meta-analysis

Efficacy of sildenafil in persistent pulmonary hypertension of the newborn.

Effectiveness of oral sildenafil for neonates with persistent pulmonary hypertension of newborn (PPHN): a prospective study in a tertiary care hospital

Use of sildenafil for the treatment of neonatal persistent pulmonary hypertension

The outcome of oral sildenafil therapy on persistent pulmonary hypertension of the newborn with respiratory distress

Effect of Sildenafil in Neonates with Persistent Pulmonary Hypertension: An Interventional Study

Comparison of the Effectiveness of Bosentan and Sildenafil in the Management of Persistent Pulmonary Arterial Hypertension in Neonates

Oral Sildenafil in Infants With Persistent Pulmonary Hypertension of the Newborn: A Pilot Randomized Blinded Study

Efficacy and Safety of IV Sildenafil in the Treatment of Newborn Infants with, or at Risk of, Persistent Pulmonary Hypertension of the Newborn (PPHN): A Multicenter, Randomized, Placebo-Controlled Trial

Study on sildenafil combined with inhalational nitric oxide therapy on the curative effects and serum levels of HIF-1α, ET-1, and calcium in neonatal pulmonary hypertension

Genomic DNA extraction fromVictoria amazonica

Perforation of the right ventricular free wall by an ICD lead in a patient with isolated noncompaction of the ventricular myocardium.

The use of Sildenafil in the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Review of the Literature

Comparison of treprostinil and oral sildenafil for the treatment of persistent pulmonary hypertension of the newborn: a retrospective cohort study

Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction : In-hospital and 30-day results of the PAMI stent pilot trial

The Progress in the Treatment of Persistent Pulmonary Hypertension in Neonatal

Comparison of tadalafil and sildenafil in controlling neonatal persistent pulmonary hypertension

Comparison of Efficacy between Sildenafil Alone and Sildenafil with Milrinone for Treatment of Persistent Pulmonary Hypertension of the Newborn

Safety and effect of sildenafil on treating paediatric pulmonary arterial hypertension: a meta-analysis on the randomised controlled trials

Effect of Sildenafil on Mortality in Term Neonates with Hypoxemic Respiratory Failure due to Persistent Pulmonary Hypertension (SIPHON) - A Randomised Control Trial